Mannkind Corp
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
4.07
-0.08
(-1.928%)
Volume:
3,541,613
52 week range:
2.49 - 5.44
Market Cap:
1.028B
Company Description:
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.